Cargando…
Identifying compounds that prevent the binding of the SARS-CoV-2 S-protein to ACE2
We investigated compounds selected by molecular docking to identify a specific treatment for COVID-19 that decreases the interaction between angiotensin-converting enzyme 2 (ACE2) and the receptor-binding domain (RBD) of SARS-CoV-2. Five compounds that interact with ACE2 amino acids Gln24, Asp30, Hi...
Autores principales: | Benítez-Cardoza, Claudia Guadalupe, Vique-Sánchez, José Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325380/ https://www.ncbi.nlm.nih.gov/pubmed/34358993 http://dx.doi.org/10.1016/j.compbiomed.2021.104719 |
Ejemplares similares
-
Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug
por: Benítez-Cardoza, Claudia Guadalupe, et al.
Publicado: (2020) -
Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2–ACE2 Receptor Interactions
por: Day, Christopher J., et al.
Publicado: (2021) -
Binding of SARS-COV-2 (COVID-19) and SARS-COV to human ACE2: Identifying binding sites and consequences on ACE2 stiffness
por: Faisal, H.M. Nasrullah, et al.
Publicado: (2021) -
Identifying Hotspots in Binding of SARS-CoV-2 Spike Glycoprotein and Human ACE2
por: Mendis, Jenny, et al.
Publicado: (2021) -
Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding
por: Yang, Li Jun, et al.
Publicado: (2021)